Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice.

Liby K, Risingsong R, Royce DB, Williams CR, Ma T, Yore MM, Sporn MB.

Cancer Prev Res (Phila). 2009 Dec;2(12):1050-8. doi: 10.1158/1940-6207.CAPR-09-0085. Epub 2009 Dec 1.

2.

The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis.

Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, Liu X, Honda T, Gribble GW, Lamph WW, Sporn TA, Dmitrovsky E, Sporn MB.

Mol Cancer Ther. 2008 May;7(5):1251-7. doi: 10.1158/1535-7163.MCT-08-0023.

3.

Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer.

Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, Sporn MB.

Cancer Prev Res (Phila). 2010 Nov;3(11):1427-34. doi: 10.1158/1940-6207.CAPR-10-0197. Epub 2010 Oct 19.

4.

The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice.

Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA, Sporn MB.

Cancer Res. 2007 Mar 15;67(6):2414-9.

5.

Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.

To C, Ringelberg CS, Royce DB, Williams CR, Risingsong R, Sporn MB, Liby KT.

Carcinogenesis. 2015 Jul;36(7):769-81. doi: 10.1093/carcin/bgv061. Epub 2015 May 4.

6.

Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.

Liby K, Risingsong R, Royce DB, Williams CR, Yore MM, Honda T, Gribble GW, Lamph WW, Vannini N, Sogno I, Albini A, Sporn MB.

Clin Cancer Res. 2008 Jul 15;14(14):4556-63. doi: 10.1158/1078-0432.CCR-08-0040.

7.

The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice.

Cao M, Royce DB, Risingsong R, Williams CR, Sporn MB, Liby KT.

Cancer Prev Res (Phila). 2016 Jan;9(1):105-14. doi: 10.1158/1940-6207.CAPR-15-0325. Epub 2015 Nov 10.

8.

A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland.

Liby K, Royce DB, Risingsong R, Williams CR, Wood MD, Chandraratna RA, Sporn MB.

Clin Cancer Res. 2007 Oct 15;13(20):6237-43.

9.

The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice.

Tran K, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K.

Cancer Prev Res (Phila). 2012 May;5(5):726-34. doi: 10.1158/1940-6207.CAPR-11-0404. Epub 2012 Mar 8.

10.

The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.

Tran K, Risingsong R, Royce DB, Williams CR, Sporn MB, Pioli PA, Gediya LK, Njar VC, Liby KT.

Carcinogenesis. 2013 Jan;34(1):199-210. doi: 10.1093/carcin/bgs319. Epub 2012 Oct 6.

12.

Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.

Liby KT, Yore MM, Sporn MB.

Nat Rev Cancer. 2007 May;7(5):357-69. Epub 2007 Apr 19. Review.

PMID:
17446857
13.

The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.

Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, Sporn MB.

Clin Cancer Res. 2006 Oct 1;12(19):5902-9.

14.

Synthetic triterpenoid CDDO prevents the progression and metastasis of prostate cancer in TRAMP mice by inhibiting survival signaling.

Deeb D, Gao X, Liu Y, Jiang D, Divine GW, Arbab AS, Dulchavsky SA, Gautam SC.

Carcinogenesis. 2011 May;32(5):757-64. doi: 10.1093/carcin/bgr030. Epub 2011 Feb 16.

15.

CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.

Kim EH, Deng C, Sporn MB, Royce DB, Risingsong R, Williams CR, Liby KT.

Cancer Prev Res (Phila). 2012 Jan;5(1):89-97. doi: 10.1158/1940-6207.CAPR-11-0359. Epub 2011 Sep 20.

16.

Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma.

Kress CL, Konopleva M, Martínez-García V, Krajewska M, Lefebvre S, Hyer ML, McQueen T, Andreeff M, Reed JC, Zapata JM.

PLoS One. 2007 Jun 27;2(6):e559.

17.

Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention.

Cao M, Onyango EO, Williams CR, Royce DB, Gribble GW, Sporn MB, Liby KT.

Pharmacol Res. 2015 Oct;100:135-47. doi: 10.1016/j.phrs.2015.07.024. Epub 2015 Jul 31.

PMID:
26238177
18.

The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection.

Tran TA, McCoy MK, Sporn MB, Tansey MG.

J Neuroinflammation. 2008 May 12;5:14. doi: 10.1186/1742-2094-5-14.

19.

The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent.

Vannini N, Lorusso G, Cammarota R, Barberis M, Noonan DM, Sporn MB, Albini A.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3139-46. Epub 2007 Dec 7.

20.

Supplemental Content

Support Center